BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Has Average Target Price of $20.75

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given an average rating of “Moderate Buy” by the nine research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $20.38.

Several research firms recently commented on BCRX. Weiss Ratings lowered BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a report on Tuesday, September 22nd. JPMorgan Chase & Co. lifted their price target on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 30th. Royal Bank Of Canada cut shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price target for the stock from $13.00 to $11.00 in a report on Thursday, September 10th. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 8th. Finally, Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday.

BioCryst Pharmaceuticals Stock Up 0.8%

BioCryst Pharmaceuticals stock opened at $7.69 on Wednesday. The company has a market capitalization of $1.97 billion, a PE ratio of -5.42 and a beta of 0.55. BioCryst Pharmaceuticals has a 12-month low of $6.23 and a 12-month high of $11.22. The firm’s fifty day moving average is $8.46 and its 200 day moving average is $8.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, November 4th. The biotechnology company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $180.29 million for the quarter, compared to the consensus estimate of $165.67 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company’s revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.06 EPS. Sell-side analysts expect that BioCryst Pharmaceuticals will post -2.28 EPS for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Nykredit A S acquired a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter worth $27,000. Winthrop Capital Management LLC purchased a new position in BioCryst Pharmaceuticals during the third quarter worth approximately $25,000. IFP Advisors Inc increased its stake in shares of BioCryst Pharmaceuticals by 2,515.3% in the second quarter. IFP Advisors Inc now owns 3,243 shares of the biotechnology company’s stock worth $32,000 after buying an additional 3,119 shares during the last quarter. Allworth Financial LP acquired a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter worth about $52,000. Finally, Pallas Capital Advisors LLC bought a new stake in BioCryst Pharmaceuticals in the second quarter worth about $101,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.